Structure Therapeutics IncNASDAQ:GPCR
- LAST PRICE34.9700
- TODAY'S CHANGE (%)-2.7200 (-7.2168%)
- Bid / Lots34.9800/ 7
- Ask / Lots35.1700/ 7
- Open / Previous Close37.7500 / 37.6900
- Day Range
- 52 Week Range
- Volume331,243
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | GPCR |
|---|---|---|
| 09:32 ET | 4708 | 37.6845 |
| 09:35 ET | 125 | 37.67 |
| 09:37 ET | 2020 | 37.0012 |
| 09:39 ET | 500 | 36.6 |
| 09:42 ET | 2492 | 36.89 |
| 09:44 ET | 200 | 36.925 |
| 09:46 ET | 400 | 36.94 |
| 09:48 ET | 200 | 36.94 |
| 09:50 ET | 300 | 36.8 |
| 09:51 ET | 2350 | 36.845 |
| 09:53 ET | 1087 | 37.03 |
| 09:55 ET | 3252 | 37 |
| 09:57 ET | 100 | 36.97 |
| 10:00 ET | 2623 | 36.5 |
| 10:02 ET | 115 | 36.46 |
| 10:04 ET | 2866 | 36.53 |
| 10:06 ET | 3835 | 36.42 |
| 10:08 ET | 406 | 36.31 |
| 10:09 ET | 6714 | 36.41 |
| 10:11 ET | 410 | 36.3301 |
| 10:13 ET | 2874 | 35.82 |
| 10:15 ET | 2736 | 35.87 |
| 10:18 ET | 3490 | 35.94 |
| 10:20 ET | 1484 | 36.1 |
| 10:22 ET | 1429 | 36 |
| 10:24 ET | 3817 | 35.5 |
| 10:26 ET | 600 | 35.4 |
| 10:27 ET | 1860 | 35.51 |
| 10:29 ET | 250 | 35.51 |
| 10:31 ET | 200 | 35.52 |
| 10:33 ET | 1924 | 35.61 |
| 10:36 ET | 2577 | 35.485 |
| 10:38 ET | 3700 | 35.3 |
| 10:40 ET | 400 | 35.46 |
| 10:42 ET | 300 | 35.3 |
| 10:44 ET | 200 | 35.3 |
| 10:45 ET | 742 | 35.3 |
| 10:47 ET | 3100 | 35.28 |
| 10:49 ET | 500 | 35.265 |
| 10:51 ET | 600 | 35.38 |
| 10:54 ET | 1458 | 34.98 |
| 10:56 ET | 709 | 34.6 |
| 10:58 ET | 1653 | 34.65 |
| 11:00 ET | 2786 | 34.615 |
| 11:02 ET | 1372 | 34.645 |
| 11:03 ET | 1760 | 34.595 |
| 11:05 ET | 2165 | 34.5 |
| 11:09 ET | 892 | 34.31 |
| 11:12 ET | 5895 | 34.43 |
| 11:14 ET | 3963 | 34.4545 |
| 11:16 ET | 4699 | 34.52 |
| 11:18 ET | 6587 | 34.67 |
| 11:20 ET | 690 | 34.91 |
| 11:21 ET | 1295 | 34.9 |
| 11:23 ET | 400 | 34.82 |
| 11:25 ET | 21840 | 34.84 |
| 11:27 ET | 500 | 34.88 |
| 11:30 ET | 4384 | 34.74 |
| 11:32 ET | 200 | 34.61 |
| 11:34 ET | 1050 | 34.63 |
| 11:36 ET | 1100 | 34.68 |
| 11:38 ET | 2981 | 34.84 |
| 11:39 ET | 4689 | 35.1299 |
| 11:41 ET | 400 | 34.97 |
| 11:43 ET | 400 | 35.085 |
| 11:45 ET | 1550 | 34.985 |
| 11:48 ET | 200 | 35.1 |
| 11:50 ET | 500 | 35.105 |
| 11:52 ET | 2308 | 35.31 |
| 11:54 ET | 100 | 35.355 |
| 11:56 ET | 3404 | 35.48 |
| 11:57 ET | 250 | 35.24 |
| 11:59 ET | 532 | 35.2125 |
| 12:01 ET | 600 | 35.25 |
| 12:03 ET | 2112 | 35.15 |
| 12:06 ET | 1000 | 35.15 |
| 12:08 ET | 8932 | 35.09 |
| 12:10 ET | 700 | 35.24 |
| 12:12 ET | 900 | 35.16 |
| 12:14 ET | 100 | 35.12 |
| 12:15 ET | 10410 | 35.015 |
| 12:17 ET | 1642 | 34.88 |
| 12:19 ET | 1119 | 35.015 |
| 12:24 ET | 100 | 34.96 |
| 12:26 ET | 300 | 35.06 |
| 12:28 ET | 900 | 35.13 |
| 12:30 ET | 781 | 35.02 |
| 12:32 ET | 1052 | 35.16 |
| 12:33 ET | 245 | 35.13 |
| 12:35 ET | 3126 | 35.045 |
| 12:37 ET | 1335 | 35.065 |
| 12:39 ET | 100 | 35.095 |
| 12:42 ET | 200 | 35.0107 |
| 12:44 ET | 200 | 35 |
| 12:51 ET | 13136 | 34.95 |
| 12:53 ET | 3228 | 35.045 |
| 12:55 ET | 100 | 34.96 |
| 12:57 ET | 1192 | 34.99 |
| 01:00 ET | 958 | 34.97 |
| 01:02 ET | 1105 | 34.91 |
| 01:04 ET | 1365 | 34.83 |
| 01:06 ET | 3575 | 35 |
| 01:08 ET | 400 | 34.985 |
| 01:09 ET | 198 | 35 |
| 01:11 ET | 200 | 35.05 |
| 01:13 ET | 900 | 34.98 |
| 01:15 ET | 3300 | 35.055 |
| 01:18 ET | 325 | 35.06 |
| 01:20 ET | 2617 | 35.075 |
| 01:24 ET | 100 | 35.02 |
| 01:26 ET | 500 | 35.08 |
| 01:27 ET | 600 | 35.21 |
| 01:29 ET | 1126 | 35.275 |
| 01:31 ET | 200 | 35.22 |
| 01:33 ET | 260 | 35.285 |
| 01:36 ET | 1513 | 35.27 |
| 01:38 ET | 783 | 35.23 |
| 01:40 ET | 791 | 35.2 |
| 01:42 ET | 1750 | 35.1885 |
| 01:44 ET | 300 | 35.17 |
| 01:45 ET | 600 | 35.08 |
| 01:47 ET | 100 | 35.08 |
| 01:49 ET | 100 | 35.03 |
| 01:51 ET | 758 | 34.94 |
| 01:54 ET | 666 | 34.99 |
| 01:56 ET | 300 | 35.04 |
| 01:58 ET | 1033 | 35 |
| 02:00 ET | 600 | 35.055 |
| 02:02 ET | 822 | 35.11 |
| 02:03 ET | 1000 | 34.97 |
Today
Nov 13, 2024
Press Release: Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights, from 4:05PM ET on Wednesday Nov 13, 2024 by Dow Jones
4:05PM ET on Wednesday Nov 13, 2024 by Dow JonesStructure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights, from 4:05PM ET on Wednesday Nov 13, 2024 by Dow Jones
4:05PM ET on Wednesday Nov 13, 2024 by Dow JonesStructure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity, from 4:01PM ET on Wednesday Nov 13, 2024 by Dow Jones
4:01PM ET on Wednesday Nov 13, 2024 by Dow Jones
Oct 31, 2024
Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek(R) 2024, from 8:30AM ET on Thursday Oct 31, 2024 by Dow Jones
8:30AM ET on Thursday Oct 31, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Structure Therapeutics Inc | 2.2B | -15.6x | --- |
Geron Corp | 2.2B | -11.6x | --- |
Akero Therapeutics Inc | 2.1B | -7.3x | --- |
Centessa Pharmaceuticals PLC | 2.2B | -10.8x | --- |
Soleno Therapeutics Inc | 2.3B | -15.8x | --- |
Longboard Pharmaceuticals Inc | 2.3B | -26.7x | --- |
Company Information
Structure Therapeutics Inc. is a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases. It is focused on G-protein coupled receptors (GPCRs) as a therapeutic target class. Its product candidates include GSBR-1290, Amylin, glucose-dependent insulinotropic polypeptide receptor (GIPR), GCGR, ANPA-0073 and LTSE-2578. It is developing GSBR-1290, its oral small molecule product candidate targeting the validated glucagon-like-peptide-1 receptor (GLP-1R) for the treatment of type 2 diabetes mellitus (T2DM) and obesity. It is developing GLP-1R candidates, including dual GLP-1R/GIPR agonists and amylin agonists, each designed with customized properties to achieve additional benefit. It is developing ANPA-0073, an investigational oral small molecule APJR agonist, for the treatment of idiopathic pulmonary fibrosis (IPF). It is evaluating its LPA1R program, LTSE-2578 for IPF and progressive pulmonary fibrosis.
Contact Information
- Headquarters
- 611 Gateway Blvd Suite 223SOUTH SAN FRANCISCO, CA, United States 94080
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- Daniel Welch
- Chief Executive Officer, Director
- Raymond Stevens
- Chief Financial Officer
- Jun Yoon
- Chief Technology Officer
- Yingli Ma
- Chief Scientific Officer
- Xichen Lin
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.2B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 57.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.24 |
Book Value | $9.76 |
P/E Ratio | -15.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
